If the tumor is left-sided, RAS, or BRAF wild-type, you should check that the patient did receive prior anti-EGFR therapy and that patients with dMMR or BRAF V600E mutated tumors have been exposed to immunotherapy and BRAF inhibitors, respectively. Here, EGFR is linked to neoplasm.